Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
6 papers
In a small, controlled study of 18 people with treatment-resistant major depression, a single intravenous dose of the NMDA receptor antagonist ketamine (0.5 mg/kg) produced rapid drops in depression scores. Improvement began within about 2 hours and remained statistically significant compared with placebo for up to 1 week. The study…
Repeated ketamine infusions have cumulative and sustained antidepressant effects. Reductions in depressive symptoms were maintained among responders through once-weekly infusions. These findings provide novel data on efficacious administration strategies for ketamine in patients with treatment-resistant depression. Future studies should further expand on optimizing administration to better translate the use of…
In this small, double-blind, placebo-controlled crossover study, 10 healthy male, infrequent cannabis users took 10 mg oral THCV daily for five days and then received 1 mg IV THC on day five. THCV was safe and felt like placebo. Compared with placebo, THCV reduced some effects of THC (for example…
We provide further preliminary evidence for the efficacy and tolerability of IM ketamine in an outpatient cohort of OCD. Additional work is required to establish the optimal dosing regimen and longer-term role of ketamine for OCD. These findings are encouraging given the well-known limitations that exist for treatments in this…
(Reprinted with permission from The American Journal of Psychiatry 2019; 176:401-409).
This small two-phase trial tested single oral doses of the Δ8 form of THCV (placebo and 12.5, 25, 50, 100, 200 mg) in healthy adults and followed participants for up to 8 hours. Most side effects were mild, some doses showed a possible short-term improvement in a sustained-attention test, and…
